All In Biotech

Drug Trial Radar · NCT01280058

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Mar 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Dec 2010

Primary completion

Jan 19, 2016

Study completion Jan 20, 2016

Sponsor

Sponsor type
NIH
First posted
Jan 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well carboplatin and paclitaxel with or without viral therapy works in treating patients with pancreatic cancer that has come back or has spread to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Viral therapy may be able to kill tumor cells without damaging normal cells. It is not yet known whether carboplatin and paclitaxel are more effective with or without viral therapy in treating pancreatic cancer.

Conditions

  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Recurrent Pancreatic Carcinoma
  • Stage IV Pancreatic Cancer

Interventions

  • CarboplatinDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • Wild-type ReovirusBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Using RECIST v. 1.1Time frame: From study entry to the date of documented progression and/or death, assessed up to 4 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Emory University/Winship Cancer Institute

    Atlanta, Georgia

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.